Bronchial Cyst

Researchers are evaluating the effect of starting Airsupra inhaler treatment in emergency departments (ED) on reducing acute asthma recurrence and other related outcomes over three months. The study focuses on adults aged 18 to 54 who visit the ED for asthma exacerbations and are discharged with a short course of systemic corticosteroids. This trial is a cluster randomized, open-label study comparing Airsupra use to usual care across multiple centers. Participants will be assigned by site to either receive usual care or Airsupra as their rescue inhaler along with corticosteroids. Airsupra dosing is as needed, with up to six doses per day. The study will run for about four to five months of enrollment per site, with follow-up assessments conducted at approximately 3, 6, and 12 weeks after the ED discharge to monitor asthma control, relapse, and recurrence. During the study, patients will complete interviews and chart reviews in the ED, and follow-up will include telephone or text contact to assess their clinical status and medication use. Medical records from before and after enrollment will be reviewed to identify asthma exacerbations. The main outcome is asthma recurrence within three months, with asthma control and early relapse also measured. Participants’ data will be securely managed throughout the study period, which extends up to 12 weeks post-ED visit.

Researchers are observing the safety and effectiveness of Atectura inhalation capsule in people aged 12 to 100 years with asthma over a 24-week period. This non-interventional, open-label study takes place across multiple centers and follows routine clinical practice without additional diagnostic or monitoring procedures beyond standard care. The study aims to gather real-world data on the use of Atectura as prescribed under approved labeling in Korea. Participants will use one of three doses of Atectura inhalation capsule delivered via Breezhaler: 150/80 µg, 150/160 µg, or 150/320 µg of indacaterol acetate/mometasone furoate. Treatments are prescribed by physicians according to routine care, and patients who have already started Atectura before joining the study will be included. No randomization or placebo control is involved since this is an observational study. During the study, researchers will track adverse events and serious adverse events over 24 weeks to evaluate safety. Lung function changes will be measured by trough FEV1 at baseline and week 12, along with asthma control using the ACT score. Effectiveness will also be assessed by investigators at week 12. Patient data on drug reactions and lung function changes will be collected to better understand treatment impact. The study runs until December 2026 and involves regular clinical assessments without extra tests beyond standard asthma care.

Researchers are observing adult patients with asthma who have been prescribed Enerzair inhalation capsules to evaluate the safety and effectiveness of this treatment over a 24-week period in real-world clinical settings. This study is open-label, prospective, multicenter, and single-arm, designed to monitor outcomes without additional interventions beyond routine care. Participants will receive one of two doses of Enerzair via Breezhaler, either 150/50/80 micrograms or 150/50/160 micrograms, as prescribed according to approved labeling in Korea. No extra diagnostic or monitoring procedures beyond standard clinical practice will be conducted during the study. Throughout the study, participants will be monitored for adverse events and serious adverse events for up to 24 weeks. Researchers will also assess lung function using trough FEV1 measurements and asthma control using the ACT score at baseline and week 12. Effectiveness will be evaluated by investigator assessment, and patient characteristics related to safety and efficacy outcomes will be recorded. The study involves collection of data without altering prescribed treatment and ensures ongoing observation in a routine care environment.

This research focuses on chronic inflammatory lung diseases such as asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis, cystic fibrosis (CF), primary ciliary dyskinesia (PCD), and interstitial lung diseases (ILD). These conditions involve inflammation and changes in lung structure with a wide range of symptoms and features. The study aims to analyze various characteristics including clinical, biological, and microbiological traits, as well as respiratory exposures and mechanisms related to airway inflammation, to better understand these diseases beyond their initial diagnosis. The study is a prospective cohort conducted at the University Hospital of Reims, France, including adults aged 18 and older diagnosed with the listed respiratory diseases or healthy volunteers as controls. Participants will be followed over a 10-year period with data collected at inclusion and follow-up visits, while controls will only provide data at inclusion. No specific treatments are given as part of the study; care continues as usual. Throughout the study, information such as demographics, disease history, lung function tests, CT scans, and respiratory sample analyses will be collected and stored in an anonymous database. Researchers will use statistical and machine learning methods to identify patient groups with similar disease patterns and predict disease progression and treatment responses. The study is planned to start in September 2025 with a recruitment period lasting five years and follow-up for a decade thereafter.

Asthma is a common condition marked by breathing difficulties, coughing, and wheezing. Diagnosing asthma relies on identifying airflow obstruction, airway sensitivity, and inflammation, but international guidelines vary in their criteria. This research evaluates how well these guidelines agree in diagnosing asthma and explores additional lung function tests like impulse oscillometry (IOS), which is not commonly included in guidelines but available at the Portsmouth lung function service. The study involves analyzing routine lung function data from patients attending the severe asthma service at Queen Alexandra Hospital in Portsmouth. It compares standard diagnostic tests recommended by international guidelines with IOS, a simple, non-invasive test measuring lung function. The goal is to see if IOS can improve the accuracy and ease of diagnosing asthma in adults. Participants' lung function data will be reviewed using both guideline-based and additional criteria, focusing on how well each method identifies asthma. Outcomes include scores based on international asthma guidelines and numbers related to non-guideline lung function tests, assessed about four weeks after recruitment. The study uses an opt-out consent process and aims to provide insights that may enhance asthma diagnosis and management.

Researchers are evaluating the efficacy and safety of benralizumab, given as a subcutaneous injection, in children aged 6 to under 18 years who have severe eosinophilic asthma. This study focuses on patients with a history of asthma attacks and uncontrolled symptoms despite using high-dose inhaled corticosteroids and at least one additional asthma controller medication. The study is a Phase III, randomized, double-blind, placebo-controlled trial designed to measure the time to first asthma exacerbation. The study includes a screening period lasting between 4 to 12 weeks to determine eligibility. Participants are randomly assigned to receive either benralizumab or a placebo injection during the double-blind treatment period, which lasts at least 16 weeks or until an asthma exacerbation occurs. Those who experience an exacerbation during this period may continue treatment in an open-label extension phase lasting at least 48 weeks, followed by an end-of-treatment visit 8 weeks after the last dose. During the study, participants will have regular visits for assessments including asthma control questionnaires, symptom scoring, lung function tests, and blood tests for benralizumab levels and antibodies. Researchers will monitor asthma exacerbations, medication use, night-time awakenings, and quality of life measures. Safety and treatment adherence will be closely observed throughout the study and the extension period, with total participation lasting over a year depending on individual progress.

Researchers are evaluating AMG 691, a drug given by subcutaneous injection, in a Phase 1 clinical trial to assess its safety and tolerability in healthy adults and adults with mild-to-moderate asthma. The study compares single and multiple doses of AMG 691 to placebo. It involves healthy participants and participants with asthma to better understand how the drug behaves in the body and its effects. The trial is randomized and double-blind, with healthy participants assigned in a 3:1 ratio to receive AMG 691 or placebo and asthma participants assigned in a 2:1 ratio. The study has different parts including single ascending dose, multiple ascending dose, and multiple dose periods. Each participant receives subcutaneous injections of either AMG 691 or placebo according to their group assignment. Participants will undergo medical evaluations, including lung function tests and blood tests, to monitor safety and drug effects over approximately 11 months. Researchers will track treatment-emergent adverse events and measure drug concentration in the blood. The study includes follow-up visits to assess safety and tolerability over time, ensuring comprehensive monitoring of participants throughout the trial.

Researchers are investigating two different doses of inhaled Glycopyrronium (GP) delivered by metered-dose inhaler (MDI) as add-on treatments to Budesonide and Formoterol Fumarate (BFF) MDI in children aged 4 to less than 12 years with asthma. This Phase II, multi-center, randomized, double-blind, crossover study aims to assess how these doses affect lung function compared to a placebo MDI added to BFF MDI. The study is designed to better understand the potential benefits and safety of these treatments in this young population with asthma. Participants will undergo a 3-week run-in period followed by three 3-week treatment periods. During the treatment periods, each participant will receive three treatments in different sequences: BFF MDI combined with GP MDI Dose A, BFF MDI combined with GP MDI Dose B, and BFF MDI combined with placebo MDI. GP MDI and BFF MDI are both administered twice daily by oral inhalation. The study concludes with a safety follow-up visit 12 to 16 days after the last dose. Throughout the study, lung function will be closely monitored, with the primary outcome being the change from baseline in forced expiratory volume in one second (FEV1) at 1-hour post-dose at the end of each 3-week treatment period. Additional measures include morning pre-dose trough FEV1 changes. Participants will attend scheduled visits for assessments, including lung function tests and safety evaluations, ensuring detailed monitoring of treatment effects and participant well-being during the study period.

Researchers are evaluating the efficacy and safety of a combination inhaler containing fluticasone propionate and albuterol sulfate delivered via a multidose dry powder inhaler with an electronic module in people aged 12 years and older who have asthma. The study is designed as a randomized, double-blind, placebo-controlled trial and aims to assess lung function improvements, safety, tolerability, and drug behavior in the body over a four-week period. Secondary goals include evaluating the combination inhaler administered four times daily and understanding the pharmacokinetics of the inhaler components after a single dose. Participants will be randomly assigned to one of four groups receiving either the combination inhaler (Fp/ABS), fluticasone propionate inhaler (Fp), albuterol sulfate inhaler (ABS), or a placebo inhaler, all with integrated electronic modules. Treatments are inhalation powders administered via dry powder inhalers. The study lasts about 10 weeks per participant, including the treatment period of four weeks and follow-up assessments. The trial includes a prescreening visit as an option before formal enrollment. During the study, participants will have their lung function measured through forced expiratory volume in one second (FEV1), asthma control assessed by questionnaires (ACQ-6 and ACT), and blood samples taken to analyze drug levels. Safety is monitored by tracking adverse events and tolerability over the treatment period. The main outcomes focus on changes in lung function at baseline and after four weeks of treatment. Participants are expected to attend multiple visits for these assessments throughout the study duration.

Researchers are evaluating the characteristics and outcomes of people with asthma, covering a wide range of disease severities. This study aims to describe participants' social and clinical profiles, treatment experiences, disease burden, biomarkers, and quality of life. It includes two parts: a cross-sectional study and a prospective follow-up to observe changes in disease progression over time. Participants continue their usual asthma care with treatments such as low, medium, or high doses of inhaled corticosteroids and/or biologic therapies. The study groups include participants with varying asthma control levels based on the Asthma Control Questionnaire-5 (ACQ-5) scores and different levels of type-2 biomarkers. No investigational drugs are given; instead, participant- and physician-reported outcomes along with blood samples and lung tests are collected. During the study, participants provide information through questionnaires and undergo assessments like lung function tests and blood sampling. Researchers measure asthma control, quality of life, symptom severity, treatment patterns, exacerbation rates, and healthcare resource use at various time points, including baseline, week 52, and week 104. The study follows participants over two years to understand disease evolution and treatment outcomes in real-world clinical practice.